Kindred Biosciences Inc

Kindred Biosciences — Investor Presentation (December 2016)

42 slides from Kindred Biosciences's investor presentation, Dec 7, 2016

  1. Slide 1: Best Medicines for Our Best Friends

    1 KindredBio KindredBio Best Medicines for Our Best Friends

  2. Slide 2: Forward Looking Statements

    2 KindredBio Forward Looking Statements This presentation contains forward-looking statements, including but not limited to statements regarding the timing of development for our product candidates, expected commencement and completion of pivotal trials, prospective product candidates, anticipated r

  3. Slide 3: We Love Our Pet Family Members

    3 KindredBio $15.7 billion on veterinary care $1.5 billion on dog knee surgeries $370 million on pet Halloween costumes $700 million on Valentine’s Day gifts Annually, U.S. pet parents estimated to spend: We Love Our Pet Family Members

  4. Slide 4: Bring the very best science and medicine to our animal family members

    4 KindredBio Bring the very best science and medicine to our animal family members. KindredBio

  5. Slide 5: KindredBio's Strategy: Repurpose Human Drugs for Pets

    5 KindredBio KindredBio’s Strategy: Repurpose Human Drugs for Pets Pursue molecules already known to work Reduce technical risk Reduce timelines $3M-$5M to develop each pet drug Reduce financing risk Portfolio approach

  6. Slide 6: KindredBio Highlights

    6 KindredBio KindredBio Highlights Two launches by 2017 Zimeta™ for fever in horses Mirataz™ for mgmt. of weight loss in cats ~2 launches per year thereafter Attractive Markets Rapidly growing Few current competitors World Class Team Extensive drug development experience Human and veterinary experie

  7. Slide 7: World Class Leadership Team

    7 KindredBio Richard Chin, M.D. Founder and Chief Executive Officer Former Head of Clinical Research, BioTherapeutics, Genentech Rhodes Scholar World Class Leadership Team 7 Denise Bevers​ Founder and Chief Operating Officer Founder, SD Scientific; 25 years in biotech/pharma Stephen Sundlof, D.V.M,

  8. Slide 8: Deep Product Pipeline

    8 KindredBio Molecule Indication Discovery/Process Development Pilot/Pivotal Clinical Studies NADA & Launch Preparation Biologic Product Candidates epoCat™ (feline erythropoietin) Anemia in cats Anti-Interleukin Antibodies Atopic dermatitis in dogs Checkpoint Inhibitors Cancer in dogs Anti-CD20 anti

  9. Slide 9: Market Opportunity

    9 KindredBio Market Opportunity

  10. Slide 10: Veterinary Market is Growing Rapidly

    10 KindredBio $9.3 [VALUE] $0 $2 $4 $6 $8 $10 $12 $14 $16 $18 2006 2015 Sp e n d in g in B ill ion s Veterinary Market is Growing Rapidly The veterinary care market grew 70% from 2006 to 2015 Source: APPA Pet Industry Market Size & Ownership Statistics 2015 & TriMark Vet Health Market, June 2013 Est

  11. Slide 11: There is a High Willingness to Pay

    11 KindredBio There is a High Willingness to Pay… $500 $1,000 $2,000 $5,000 Extremely/Very likely 62% 42% 35% 22% Somewhat likely 18% 20% 28% 20% Not too likely/Not at all likely 18% 36% 36% 55% Don’t know 1% 2% 1% 3% Pet owners are willing to spend on their seriously ill pets if they require medica

  12. Slide 12: But Treatment Options are Limited

    12 KindredBio …But Treatment Options are Limited Underserved market with attractive growth opportunities Few competing biotechs Large pharma focused on blockbusters On average, less than a dozen pet drugs are approved annually by the FDA In 2015 the FDA approved: 0 novel pet drugs 45 novel humans dr

  13. Slide 13: Veterinary Pharmaceuticals Field

    13 KindredBio Veterinary Pharmaceuticals Field We believe there are similarities between veterinary pharmaceutical field now and the human pharmaceutical field in its early stages: Similar regulatory standards Similar commercial and reimbursement landscape Similar development costs Numerous untapped

  14. Slide 14: Veterinary vs. Human Markets

    14 KindredBio Veterinary vs. Human Markets Can reach market in 3-5 years Faster Development Lower Development Cost Almost no biotechs, almost no generics Lower Competition Self-Pay Very few reimbursement hurdles Can develop for $3M-$5M per product

  15. Slide 15: Programs

    15 KindredBio Programs

  16. Slide 16: KindredBio Strategy

    16 KindredBio KindredBio Strategy Already validated in humans & established manufacturing Customize species- specific dosage and formulate flavored/convenient delivery Targets based on approved human drugs (e.g., Enbrel and Orencia) Create canine/ feline/equine versions of biologics with the same or

  17. Slide 17: KindredBio's Priority Areas

    17 KindredBio Equine Products • High willingness to pay • Similar to human orphan drug market • Efficient commercial structure Biologics • Atopic dermatitis • Cancer KindredBio’s Priority Areas

  18. Slide 18: Equine Market

    18 KindredBio Equine Market Fewer horses than cats or dogs, but higher willingness to pay – similar to human orphan drug markets Only 10-12 sales representatives required for full national coverage Underappreciated opportunity KindredBio’s goal is to become dominant company in the equine sector

  19. Slide 19: Zimeta (dipyrone injection)

    19 KindredBio Zimeta™ (dipyrone injection) IV and oral drug for treatment of pyrexia (fever) in horses High unmet medical need U.S. equine veterinarians report seeing 12 cases (median) of fever in a typical month Currently, no FDA-approved treatment for fever in horses 8-9 million horses in the U.S

  20. Slide 20: Zimeta Development Program

    20 KindredBio Zimeta Development Program IV: Positive pivotal field study completed CMC technical section of NADA filed Dec 2015 Safety technical section of NADA filed Mar 2016 Effectiveness technical section of NADA approved by FDA Oct 2016 Expect approval 2H/2017, if review proceeds as expected Or

  21. Slide 21: Zimeta Pilot Study Results (IV)

    21 KindredBio Zimeta Pilot Study Results (IV) Mean Temp. over Time - First Dose and Crossover Dose (Treated Pts.) Zimeta

  22. Slide 22: Zimeta Pivotal Field Study Results (IV)

    22 KindredBio Zimeta Pivotal Field Study Results (IV) KB0120 study: Randomized, double-blind, placebo-controlled (N=138) Primary endpoint was improvement or resolution of fever Placebo Zimeta n 34 104 Success Rate (%) 7 (20.6) 78 (75.0) p-value < 0.0001

  23. Slide 23: Mirataz (mirtazapine transdermal ointment)

    23 KindredBio Mirataz™ (mirtazapine transdermal ointment) Transdermal drug for the management of weight loss in cats Innovative Accusorb™ transdermal technology High unmet medical need Current drugs often not effective 90% of veterinarians treat cats with inappetence (average of 7 cats per week) 9 m

  24. Slide 24: Mirataz Development Program

    24 KindredBio Mirataz Development Program Positive pivotal field study completed CMC technical section of NADA filed May 2016 Effectiveness technical section of NADA filed Aug 2016 Safety technical section of NADA filed Sep 2016 Expect approval 2H/2017 if review proceeds as expected

  25. Slide 25: Mirataz Pivotal Field Study Results

    25 KindredBio Mirataz Pivotal Field Study Results Randomized, double-blind, placebo-controlled study (N=231) Primary endpoint was percentage change in body weight from Day 1 to Week 2 Placebo Mirataz Primary analysis population n=97 n=90 Mean % increase in body weight from Day 1 to Week 2 (SE) 0.29

  26. Slide 26: Biologics

    26 KindredBio Biologics Highly experienced biologics team Extensive experience developing Lucentis®, Xolair®, Tysabri®, Avastin®, Rituxan®, Herceptin®, Enbrel®, and multiple other biologics Internal caninization/felinization/equinization expertise Promising biologics candidates Feline erythropoietin

  27. Slide 27: New Scaffold Technology: KIND-Body

    27 KindredBio New Scaffold Technology: KIND-Body A proprietary, non-antibody scaffold technology being developed by KindredBio Binding affinity similar to antibodies Bispecific binding possible Could allow KindredBio to pursue biologics targets before other parties’ antibody patents expire

  28. Slide 28: KIND-510: Feline Erythropoietin

    28 KindredBio KIND-510: Feline Erythropoietin Proprietary recombinant feline erythropoietin (epoCat™) Strong internal expertise in erythropoietin biology and engineering Initial laboratory study completed - positive efficacy signal, as evidenced by increased reticulocyte formation Pilot field study

  29. Slide 29: KIND-511: Anti-TNF for Newborn Foals

    29 KindredBio KIND-511: Anti-TNF for Newborn Foals Sick newborn foals are challenging and difficult to treat Approximately 50% mortality Pilot field study for Anti-Tumor Necrosis Factor (Anti-TNF) underway Sick foals defined as sepsis score ≥ 11 or positive blood culture Of 5 foals enrolled, all sur

  30. Slide 30: Key Focus Area: Atopic Dermatitis

    30 KindredBio Key Focus Area: Atopic Dermatitis Atopic dermatitis is a large market Apoquel® projected peak sales >$200M Multiple antibody candidates Anti-IgE antibody Anti-IL17a antibody Anti-IL4Ra antibody Anti-IL31 antibody Anti-CD20 antibody Multi-center, pilot field study underway to assess saf

  31. Slide 31: Key Focus Area: Cancer

    31 KindredBio Key Focus Area: Cancer Multiple antibody candidates Anti-CTLA4 antibody Anti-PD1 antibody Anti-PDL1 antibody Anti-CD20 antibody

  32. Slide 32: Biologics Manufacturing Plant

    32 KindredBio Biologics Manufacturing Plant In-house biologics manufacturing plant nearly complete Single-use, state of the art system Will allow full GMP commercial production of feline epo (epoCat™) Will allow full GMP clinical and early commercial production of antibodies

  33. Slide 33: Commercialization

    33 KindredBio Commercialization

  34. Slide 34: Commercialization

    34 KindredBio Commercialization Equine Commercialization: Launch and commercialize our U.S. products with ~10 person direct sales force Dog/Cat Commercialization Options: Self-Commercialization Out-license Partner for 3 – 5 years, and then transition to KindredBio salesforce

  35. Slide 35: Low Generic Penetration

    35 KindredBio Few pet generic companies No automatic substitution Requires sales & marketing effort Rimadyl reached peak sales several years after loss of exclusivity Low Generic Penetration Note: Companion Animal dispensing rate within the veterinary clinic. Source: IMS Health, Putney, BofA Merril

  36. Slide 36: Exclusivity and IP Position

    36 KindredBio Exclusivity and IP Position Full intellectual property protection anticipated for antibody portfolio Use and formulation patents for small molecules 20 years of patent protection from date of filing Regulatory Exclusivity 5 years in U.S. 10 years in E.U. Lifecycle Management New formul

  37. Slide 37: Business Development

    37 KindredBio Business Development In active discussions about acquisitions of businesses and/or assets, particularly of equine assets Ideal candidate: Revenue generating/accretive Commercial infrastructure Complementary assets

  38. Slide 38: Financials

    38 KindredBio Financials

  39. Slide 39: Select Summary Financials

    39 KindredBio Select Summary Financials $ millions For the quarter ended September 30, 2016 Operating expenses: Research and development $3.8 General and administrative $2.0 Total cash operating expenses (excluding stock-based compensation) $4.8 Total operating expenses (including stock-based compen

  40. Slide 40: Share Structure & Stock History

    40 KindredBio Share Structure & 6 Month Stock History 19.9 M Shares Outstanding 3.6 M Options1 US$107.4 M Market Cap2 US$58.7 M Working Capital3 1 As of September 30, 2016; avg. $6.35 2 As of close of market October 31, 2016 3 As of September 30, 2016 Analyst Coverage Alex Arfaei, BMO Capital Market

  41. Slide 41: Summary

    41 KindredBio Summary Validated Drugs and Targets $3M-$5M to Market Multiple Approvals Starting within 1 year World Class Team

  42. Slide 42: Thank You

    42 KindredBio Thank You

Kindred Biosciences — Investor Presentation (December 2016) on 6ix